Close X

Attorney Spotlight

How does Eli Richardson's past work with the federal government inform his client interactions? Find out more>

Search

Close X

Experience

Search our Experience

Experience Spotlight

In June 2016, AmSurg Corp. and Envision Healthcare Holdings, Inc. (Envision) announced they have signed a definitive merger agreement pursuant to which the companies will combine in an all-stock transaction. Upon completion of the merger, which is expected to be tax-free to the shareholders of both organizations, the combined company will be named Envision Healthcare Corporation and co-headquartered in Nashville, Tennessee and Greenwood Village, Colorado. The company's common stock is expected to trade on the New York Stock Exchange under the ticker symbol: EVHC. Bass, Berry & Sims served as lead counsel on the transaction, led by Jim Jenkins. Read more.

AmSurg logo


Close X

Thought Leadership

Enter your search terms in the relevant box(es) below to search for specific Thought Leadership.
To see a recent listing of Thought Leadership, click the blue Search button below.

Thought Leadership Spotlight

Inside the FCA blogInside the FCA blog features ongoing updates related to the False Claims Act (FCA), including insight on the latest legal decisions, regulatory developments and FCA settlements. The blog provides timely updates for corporate boards, directors, compliance managers, general counsel and other parties interested in the organizational impact and legal developments stemming from issues potentially giving rise to FCA liability.

Read More >

Sixth Circuit Articulates New Standard for Evaluating Corporate Scienter in Securities Fraud Claims

Publications

October 17, 2014

On October 10, 2014, the Sixth Circuit revisited the standard for pleading scienter and a material misrepresentation or omission to support a securities-fraud claim under Section 10(b) of the Securities Exchange Act of 1934 and SEC Rule 10b-5.  See In Re: Omnicare, Inc. Securities Litigation, No. 13-5597, 2014 U.S. App. LEXIS 19326 (6th Cir. Oct. 10, 2014).  The panel observed that despite the multiple decisions that have come out of the Sixth Circuit to date, these pleading requirements "remain somewhat hazy and muddled."  In an effort to "clear[] away any confusion" that has come out of prior Sixth Circuit decisions, the court went through the base line needed to satisfy these elements under the Private Securities Litigation Reform Act of 1995.  The court then adopted a new standard in the Sixth Circuit for determining whether a corporation has acted with the requisite scienter.

Currently, a circuit split exists with respect to the standard for the doctrine of collective corporate scienter.  The Omnicare panel adopted a new middle approach for the Sixth Circuit that has three categories of individuals whose states of mind could give rise to a strong inference that a defendant corporation acted with the requisite scienter.  Those categories include the following:

  • The individual agent who uttered or issued the misrepresentation;
  • Any individual agent who authorized, requested, commanded, furnished information for, prepared (including suggesting or contributing language for inclusion therein or omission therefrom), reviewed, or approved the statement in which the misrepresentation was made before its utterance or issuance;
  • Any high managerial agent or member of the board of directors who ratified, recklessly disregarded, or tolerated the misrepresentation after its utterance or issuance.

Out of these three categories, the first one is more likely to establish corporate scienter as it relies on the state of mind of the individual officer making the statement. Depending on the circumstances of each case, the last two categories are designed to permit a finding of scienter when corporations permit shielding of bad news from management. The Sixth Circuit stated that this new approach is intended to "protect[] corporations from liability—or strike suits—when one individual unknowingly makes a false statement that another individual, unrelated to the preparation or issuance of the statement knew to be false or misleading" but also should "prevent[] corporations from evading liability through tacit encouragement and willful ignorance."

When evaluating the alleged securities fraud at issue in the case, the court further cautioned that companies cannot simply "attach[] throat-clearing language to their public utterances" by including phrases in a statement such as "we believe" or "the government might have a different view" to insulate the corporation or its officers from potential liability. The panel, however, affirmed dismissal because, even if the alleged statement had been misleading, the plaintiffs still did not adequately plead scienter against the individual defendants or the company under its new corporate scienter standard. It should be noted that only the Sixth Circuit has explicitly adopted this new corporate scienter approach, and it remains to be seen whether any other circuit will endorse it or whether the Supreme Court may ultimately weigh in on this circuit split.


Related Services

Notice

Visiting, or interacting with, this website does not constitute an attorney-client relationship. Although we are always interested in hearing from visitors to our website, we cannot accept representation on a new matter from either existing clients or new clients until we know that we do not have a conflict of interest that would prevent us from doing so. Therefore, please do not send us any information about any new matter that may involve a potential legal representation until we have confirmed that a conflict of interest does not exist and we have expressly agreed in writing to the representation. Until there is such an agreement, we will not be deemed to have given you any advice, any information you send may not be deemed privileged and confidential, and we may be able to represent adverse parties.